Chronic dosing with mirtazapine does not produce sedation in rats
Braz. J. Psychiatry (São Paulo, 1999, Impr.)
; Braz. J. Psychiatry (São Paulo, 1999, Impr.);39(3): 228-236, July-Sept. 2017. graf
Article
en En
| LILACS
| ID: biblio-899351
Biblioteca responsable:
BR1.1
ABSTRACT
Objective:
Sedation/somnolence are major side effects of pharmacotherapies for depression, and negatively affect long-term treatment compliance in depressed patients. Use of mirtazapine (MIR), an atypical antidepressant approved for the treatment of moderate to severe depression with comorbid anxiety disorders, is associated with significant sedation/somnolence, especially in short-term therapy. Nonetheless, studies with human subjects suggest that MIR-induced sedation is transient, especially when high and repeated doses are used. The purpose of this study was to explore the effects of acute and chronic administration of different doses of MIR on sedation in the rat.Methods:
Assessment of sedation was carried out behaviorally using the rotarod, spontaneous locomotor activity, and fixed-bar tests.Results:
A 15-mg/kg dose of MIR induced sedative effects for up to 60 minutes, whereas 30 mg/kg or more produced sedation within minutes and only in the first few days of administration.Conclusion:
These results suggest that 30 mg/kg is a safe, well-tolerated dose of MIR which generates only temporary sedative effects.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
LILACS
Asunto principal:
Hipnóticos y Sedantes
/
Locomoción
/
Mianserina
/
Antidepresivos Tricíclicos
Límite:
Animals
Idioma:
En
Revista:
Braz. J. Psychiatry (São Paulo, 1999, Impr.)
/
Brazilian Journal of Psychiatry (São Paulo. 1999. Impresso)
/
Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
/
Rev Bras Psiquiatr
/
Revista Brasileira de Psiquiatria
Asunto de la revista:
PSIQUIATRIA
Año:
2017
Tipo del documento:
Article
País de afiliación:
México
Pais de publicación:
Brasil